Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim WS, Nagler A, Dimou M, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Munoz J, Rodrigues L, Hiemeyer F, Miriyala A, Garcia-Vargas J, Childs BH, Zinzani PL.

Am J Hematol. 2019 Dec 23. doi: 10.1002/ajh.25711. [Epub ahead of print]

PMID:
31868245
2.

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer.

Facciotto C, Casado J, Turunen L, Leivonen SK, Tumiati M, Rantanen V, Kauppi L, Lehtonen R, Leppä S, Wennerberg K, Hautaniemi S.

Clin Epigenetics. 2019 Dec 11;11(1):192. doi: 10.1186/s13148-019-0781-3.

3.

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.

Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G.

J Clin Oncol. 2019 Nov 1;37(31):2815-2824. doi: 10.1200/JCO.19.01073. Epub 2019 Jul 24.

PMID:
31339826
4.

Pixantrone beyond monotherapy: a review.

Barrenetxea Lekue C, Grasso Cicala S, Leppä S, Stauffer Larsen T, Herráez Rodríguez S, Alonso Caballero C, Jørgensen JM, Toldbod H, Leal Martínez I, D'Amore F.

Ann Hematol. 2019 Sep;98(9):2025-2033. doi: 10.1007/s00277-019-03749-0. Epub 2019 Jul 17. Review.

5.

Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.

Alkodsi A, Cervera A, Zhang K, Louhimo R, Meriranta L, Pasanen A, Leivonen SK, Holte H, Leppä S, Lehtonen R, Hautaniemi S.

Leukemia. 2019 Nov;33(11):2662-2672. doi: 10.1038/s41375-019-0509-6. Epub 2019 Jun 11.

PMID:
31186494
6.

Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.

Mannisto S, Vähämurto P, Pollari M, Clausen MR, Jyrkkiö S, Kellokumpu-Lehtinen PL, Kovanen P, Karjalainen-Lindsberg ML, d'Amore F, Leppä S.

Eur J Cancer. 2019 Jul;115:27-36. doi: 10.1016/j.ejca.2019.04.004. Epub 2019 May 10.

PMID:
31082690
7.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, Leppä S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Dührsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W; PHOENIX investigators.

J Clin Oncol. 2019 May 20;37(15):1285-1295. doi: 10.1200/JCO.18.02403. Epub 2019 Mar 22.

8.

Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras.

Vähämurto P, Mannisto S, Pollari M, Karjalainen-Lindsberg ML, Mäkitie AA, Leppä S.

Eur J Haematol. 2019 Jun;102(6):457-464. doi: 10.1111/ejh.13225. Epub 2019 Apr 9.

PMID:
30834564
9.

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.

Leivonen SK, Pollari M, Brück O, Pellinen T, Autio M, Karjalainen-Lindsberg ML, Mannisto S, Kellokumpu-Lehtinen PL, Kallioniemi O, Mustjoki S, Leppä S.

Haematologica. 2019 Feb;104(2):338-346. doi: 10.3324/haematol.2018.200105. Epub 2018 Sep 20.

10.

PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.

Pollari M, Brück O, Pellinen T, Vähämurto P, Karjalainen-Lindsberg ML, Mannisto S, Kallioniemi O, Kellokumpu-Lehtinen PL, Mustjoki S, Leivonen SK, Leppä S.

Haematologica. 2018 Nov;103(11):1908-1914. doi: 10.3324/haematol.2018.197194. Epub 2018 Jul 19.

11.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.

Madsen C, Clausen MR, Plesner TL, Pasanen A, Kuismanen T, Bentzen HH, Jørgensen JM, Sillesen IB, Himmelstrup BM, Rønnov-Jessen D, Jensen KR, Pettinger AM, Ludvigsen M, Leppä S, d'Amore FA.

Blood Adv. 2018 Jul 10;2(13):1562-1571. doi: 10.1182/bloodadvances.2018017673.

12.

Identifying differentially methylated sites in samples with varying tumor purity.

Häkkinen A, Alkodsi A, Facciotto C, Zhang K, Kaipio K, Leppä S, Carpén O, Grénman S, Hynninen J, Hietanen S, Lehtonen R, Hautaniemi S.

Bioinformatics. 2018 Sep 15;34(18):3078-3085. doi: 10.1093/bioinformatics/bty310.

PMID:
29912358
13.

MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma.

Leivonen SK, Icay K, Jäntti K, Siren I, Liu C, Alkodsi A, Cervera A, Ludvigsen M, Hamilton-Dutoit SJ, d'Amore F, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S.

Blood Cancer J. 2017 Dec 15;7(12):654. doi: 10.1038/s41408-017-0033-8.

14.

Clinical significance of gene defects in B-cell lymphomas.

Pasanen A, Meriranta L, Leppä S.

Duodecim. 2017;133(9):839-46. Review. Finnish.

PMID:
29239593
15.

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS.

Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.

16.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4. Erratum in: J Clin Oncol. 2018 Feb 10;36(5):521.

PMID:
28976790
17.

Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.

Leivonen SK, Taskinen M, Cervera A, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S.

Blood Cancer J. 2017 Aug 25;7(8):e596. doi: 10.1038/bcj.2017.71.

18.

Clinical findings in 25 patients with sinonasal or nasopharyngeal extramedullary plasmacytoma in a four-decade single-centre series.

Vento SI, Vähämurto P, Silventoinen K, Karjalainen-Lindsberg ML, Mannisto S, Leppä S, Mäkitie AA.

Acta Otolaryngol. 2017 Sep;137(9):975-980. doi: 10.1080/00016489.2017.1325514. Epub 2017 May 24.

PMID:
28537101
19.

Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.

Moffitt AB, Ondrejka SL, McKinney M, Rempel RE, Goodlad JR, Teh CH, Leppa S, Mannisto S, Kovanen PE, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Iqbal J, Yu J, Naresh K, Villa D, Gascoyne RD, Said J, Czader MB, Chadburn A, Richards KL, Rajagopalan D, Davis NS, Smith EC, Palus BC, Tzeng TJ, Healy JA, Lugar PL, Datta J, Love C, Levy S, Dunson DB, Zhuang Y, Hsi ED, Dave SS.

J Exp Med. 2017 May 1;214(5):1371-1386. doi: 10.1084/jem.20160894. Epub 2017 Apr 19.

20.

Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma.

Meriranta L, Pasanen A, Louhimo R, Cervera A, Alkodsi A, Autio M, Taskinen M, Rantanen V, Karjalainen-Lindsberg ML, Holte H, Delabie J, Lehtonen R, Hautaniemi S, Leppä S.

Haematologica. 2017 May;102(5):e195-e198. doi: 10.3324/haematol.2016.157495. Epub 2017 Feb 9. No abstract available.

21.

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MDC, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A.

J Clin Oncol. 2017 Feb 10;35(5):544-551. doi: 10.1200/JCO.2016.69.0198. Epub 2016 Dec 28.

PMID:
28029326
22.

Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.

Pauly F, Fjordén K, Leppä S, Holte H, Björkholm M, Fluge Ø, Møller Pedersen L, Eriksson M, Isinger-Ekstrand A, Borrebaeck CA, Jerkeman M, Wingren C.

Blood Cancer J. 2016 Nov 18;6(11):e501. doi: 10.1038/bcj.2016.113. No abstract available.

23.

FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders.

Lehtonen JM, Forsström S, Bottani E, Viscomi C, Baris OR, Isoniemi H, Höckerstedt K, Österlund P, Hurme M, Jylhävä J, Leppä S, Markkula R, Heliö T, Mombelli G, Uusimaa J, Laaksonen R, Laaksovirta H, Auranen M, Zeviani M, Smeitink J, Wiesner RJ, Nakada K, Isohanni P, Suomalainen A.

Neurology. 2016 Nov 29;87(22):2290-2299. Epub 2016 Oct 28.

24.

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes Da Silva M, Mounier C, Offner F, Dupuis J, Caballero D, Canioni D, Paula M, Delarue R, Zachee P, Seymour J, Salles G, Tilly H.

J Clin Oncol. 2016 Aug 1;34(22):2575-82. doi: 10.1200/JCO.2015.65.7163. Epub 2016 Jun 13. Erratum in: J Clin Oncol. 2016 Sep 10;34(26):3230.

PMID:
27298402
25.

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.

Crump M, Leppä S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SP, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T.

J Clin Oncol. 2016 Jul 20;34(21):2484-92. doi: 10.1200/JCO.2015.65.7171. Epub 2016 May 23.

PMID:
27217449
26.

Clinical findings of extranodal SNT lymphoid malignancies in a four-decade single-centre series.

Vähämurto P, Silventoinen K, Vento SI, Karjalainen-Lindsberg ML, Haapaniemi A, Bäck L, Mannisto S, Leppä S, Mäkitie AA.

Eur Arch Otorhinolaryngol. 2016 Nov;273(11):3839-3845. Epub 2016 Mar 24.

PMID:
27010643
27.

Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma.

Peroja P, Haapasaari KM, Mannisto S, Miinalainen I, Koivunen P, Leppä S, Karjalainen-Lindsberg ML, Kuusisto ME, Turpeenniemi-Hujanen T, Kuittinen O, Karihtala P.

Virchows Arch. 2016 May;468(5):623-30. doi: 10.1007/s00428-016-1920-2. Epub 2016 Mar 16.

PMID:
26983700
28.

Allogeneic Haematopoietic Stem Cell Transplantation for Patients with Cutaneous T-cell Lymphoma.

Väkevä L, Niittyvuopio R, Leppä S, Heiskanen J, Lindström V, Ranki A, Volin L.

Acta Derm Venereol. 2016 Aug 23;96(6):816-7. doi: 10.2340/00015555-2362. No abstract available.

29.

HIV infection and cancer.

Sutinen J, Leppä S, Tarkkanen M.

Duodecim. 2016;132(18):1647-52.

PMID:
29188942
30.

Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.

Harjama L, Kuitunen H, Turpeenniemi-Hujanen T, Haapasaari KM, Leppä S, Mannisto S, Karjalainen-Lindsberg ML, Lehtinen T, Eray M, Vornanen M, Haapasalo H, Soini Y, Jantunen E, Nousiainen T, Vasala K, Kuittinen O.

Acta Oncol. 2015 Jun;54(6):939-43. doi: 10.3109/0284186X.2014.990110. Epub 2015 Mar 11.

PMID:
25761092
31.

Identification of homozygous deletion in ACAN and other candidate variants in familial classical Hodgkin lymphoma by exome sequencing.

Ristolainen H, Kilpivaara O, Kamper P, Taskinen M, Saarinen S, Leppä S, d'Amore F, Aaltonen LA.

Br J Haematol. 2015 Aug;170(3):428-31. doi: 10.1111/bjh.13295. Epub 2015 Feb 25. No abstract available.

PMID:
25715982
32.

Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.

Küçük C, Jiang B, Hu X, Zhang W, Chan JK, Xiao W, Lack N, Alkan C, Williams JC, Avery KN, Kavak P, Scuto A, Sen E, Gaulard P, Staudt L, Iqbal J, Zhang W, Cornish A, Gong Q, Yang Q, Sun H, d'Amore F, Leppä S, Liu W, Fu K, de Leval L, McKeithan T, Chan WC.

Nat Commun. 2015 Jan 14;6:6025. doi: 10.1038/ncomms7025.

PMID:
25586472
33.

[Prognostic factors and treatment of diffuse large cell B-cell lymphoma].

Riihijärvi S, Leppä S.

Duodecim. 2014;130(21):2181-9. Review. Finnish.

PMID:
25582012
34.

Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.

Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, Fagerli UM.

Haematologica. 2015 Apr;100(4):534-40. doi: 10.3324/haematol.2014.108472. Epub 2014 Dec 5.

35.

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.

Riihijärvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg ML, Delabie J, Smeland E, Holte H, Leppä S.

Haematologica. 2015 Feb;100(2):238-45. doi: 10.3324/haematol.2014.113472. Epub 2014 Nov 7.

36.

(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppä S, Jyrkkiö S, Holte H, Eriksson M, Gillstrøm D, Hansen PB, Seppänen M, Hjorthaug K, Brown Pde N, Pedersen LM.

Leuk Lymphoma. 2015 Jul;56(7):2005-12. doi: 10.3109/10428194.2014.975800. Epub 2014 Nov 20.

PMID:
25330442
37.

Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.

Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppä S, Liestøl K, Smeland EB, Holte H.

Leuk Lymphoma. 2015 Jun;56(6):1742-9. doi: 10.3109/10428194.2014.970550. Epub 2014 Nov 19.

PMID:
25284491
38.

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.

Sarkozy C, Seymour JF, Ferme C, Caballero D, Ghesquieres H, Leppa S, Delarue R, Pedersen LM, Mounier C, Gomes Da Silva M, Chassagne-Clement C, Maerevoet M, Salles G.

Blood. 2014 Apr 24;123(17):2740-2. doi: 10.1182/blood-2014-02-553693. No abstract available.

PMID:
24764560
39.

Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.

Taskinen M, Louhimo R, Koivula S, Chen P, Rantanen V, Holte H, Delabie J, Karjalainen-Lindsberg ML, Björkholm M, Fluge Ø, Pedersen LM, Fjordén K, Jerkeman M, Eriksson M, Hautaniemi S, Leppä S.

PLoS One. 2014 Mar 13;9(3):e91031. doi: 10.1371/journal.pone.0091031. eCollection 2014.

40.

Primary mediastinal large B-cell lymphoma segregating in a family: exome sequencing identifies MLL as a candidate predisposition gene.

Saarinen S, Kaasinen E, Karjalainen-Lindsberg ML, Vesanen K, Aavikko M, Katainen R, Taskinen M, Kytölä S, Leppä S, Hietala M, Vahteristo P, Aaltonen LA.

Blood. 2013 Apr 25;121(17):3428-30. doi: 10.1182/blood-2012-06-437210. Epub 2013 Mar 1.

PMID:
23457195
41.

Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP.

Castillo JJ, Sinclair N, Beltrán BE, Song MK, Ilic I, Leppa S, Nurmi H, Seki R, Uccella S, Li JM, Treaba DO, Stachurski D, Butera JN.

Leuk Res. 2013 Apr;37(4):386-91. doi: 10.1016/j.leukres.2013.01.002. Epub 2013 Jan 24.

PMID:
23352640
42.

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.

Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M.

Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17.

PMID:
23247661
43.

High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy.

Riihijärvi S, Nurmi H, Holte H, Björkholm M, Fluge O, Pedersen LM, Rydström K, Jerkeman M, Eriksson M, Leppä S.

Eur J Haematol. 2012 Nov;89(5):395-402. doi: 10.1111/ejh.12005. Epub 2012 Sep 14.

PMID:
22882209
44.

The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Castillo JJ, Beltran BE, Song MK, Ilic I, Leppa S, Nurmi H, Seki R, Uccella S, Li JM, Treaba DO, Stachurski D, Butera JN.

Leuk Res. 2012 Apr;36(4):413-7. doi: 10.1016/j.leukres.2011.12.012. Epub 2012 Jan 24.

PMID:
22277681
45.

Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.

Koivula S, Valo E, Raunio A, Hautaniemi S, Leppä S.

Oncol Rep. 2011 Apr;25(4):1183-90. doi: 10.3892/or.2011.1179. Epub 2011 Feb 10.

PMID:
21318224
46.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H.

Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20. Erratum in: Lancet. 2011 Apr 2;377(9772):1154.

PMID:
21176949
47.

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy.

Riihijärvi S, Taskinen M, Jerkeman M, Leppä S.

Eur J Haematol. 2011 Feb;86(2):124-8. doi: 10.1111/j.1600-0609.2010.01541.x. Epub 2010 Dec 22.

PMID:
20942853
48.

Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy.

Taskinen M, Jantunen E, Kosma VM, Bono P, Karjalainen-Lindsberg ML, Leppä S.

Eur J Cancer. 2010 Sep;46(13):2506-12. doi: 10.1016/j.ejca.2010.06.014. Epub 2010 Jul 12.

PMID:
20630741
49.

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Rydström K, Linderoth J, Nyman H, Ehinger M, Joost P, Bendahl PO, Leppä S, Jerkeman M.

Leuk Lymphoma. 2010 Sep;51(9):1643-8. doi: 10.3109/10428194.2010.492537.

PMID:
20593977
50.

Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP.

Taskinen M, Valo E, Karjalainen-Lindsberg ML, Hautaniemi S, Meri S, Leppä S.

Clin Cancer Res. 2010 May 1;16(9):2615-23. doi: 10.1158/1078-0432.CCR-09-3269. Epub 2010 Apr 13.

Supplemental Content

Support Center